BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth L. Londoner acquired 6,000 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The stock was purchased at an average price of $6.88 per share, for a total transaction of $41,280.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
BSGM stock opened at $6.87 on Monday. BioSig Technologies Inc has a 52 week low of $3.50 and a 52 week high of $9.97. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.99 and a quick ratio of 10.99.
BioSig Technologies (NASDAQ:BSGM) last released its quarterly earnings results on Monday, April 15th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Analysts forecast that BioSig Technologies Inc will post -1.17 earnings per share for the current year.
BSGM has been the topic of several recent research reports. Laidlaw set a $11.00 price objective on shares of BioSig Technologies and gave the company a “buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research downgraded shares of BioSig Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th.
About BioSig Technologies
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
Featured Article: Cost of Goods Sold (COGS)
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.